HOLX · As filed with the SEC
Hologic cash flow statement, by fiscal year
The statement as Hologic presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Sep 27, 2025 | FY2024 Year ended Sep 28, 2024 | FY2023 Year ended Sep 30, 2023 | FY2022 Year ended Sep 24, 2022 |
|---|---|---|---|---|
| OPERATING ACTIVITIES | ||||
| Net income | 565,700,000 | 789,500,000 | 456,000,000 | 1,302,000,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation | 108,900,000 | 99,300,000 | 89,600,000 | 89,200,000 |
| Amortization of acquired intangible assets | 190,900,000 | 209,700,000 | 233,800,000 | 340,900,000 |
| Stock-based compensation expense | 84,300,000 | 82,300,000 | 79,600,000 | 66,700,000 |
| Deferred income taxes and other non-cash taxes | (141,600,000) | (72,100,000) | (109,100,000) | (166,200,000) |
| Intangible assets and equipment impairment charges | 225,900,000 | 44,800,000 | 223,800,000 | 45,100,000 |
| Loss on assets held-for-sale | 0 | 0 | 51,700,000 | — |
| Contingent consideration fair value adjustments | 0 | 1,700,000 | (14,900,000) | (39,500,000) |
| Debt extinguishment loss | — | 0 | 0 | 700,000 |
| Other adjustments and non-cash items | 43,400,000 | 45,900,000 | 28,900,000 | 32,600,000 |
| Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions: | ||||
| Accounts receivable | 7,800,000 | 41,000,000 | (1,500,000) | 272,300,000 |
| Inventory | (1,300,000) | (47,400,000) | (4,900,000) | (136,600,000) |
| Prepaid income taxes | 20,100,000 | (21,700,000) | 17,400,000 | (23,300,000) |
| Prepaid expenses and other assets | 11,900,000 | 7,300,000 | 23,600,000 | 384,300,000 |
| Accounts payable | (11,300,000) | 22,200,000 | (23,000,000) | (14,400,000) |
| Accrued expenses and other liabilities | (32,300,000) | 73,400,000 | (14,200,000) | (15,800,000) |
| Deferred revenue | (15,300,000) | 9,300,000 | 14,400,000 | (12,300,000) |
| Net cash provided by operating activities | 1,057,100,000 | 1,285,200,000 | 1,051,200,000 | 2,125,700,000 |
| INVESTING ACTIVITIES | ||||
| Acquisition of businesses, net of cash acquired | (321,500,000) | (297,300,000) | (5,000,000) | (158,600,000) |
| Net proceeds from sale of business | — | — | — | 0 |
| Sale of business, net of cash disposed | 0 | (31,300,000) | — | — |
| Purchases of available-for-sale securities | (146,900,000) | (267,700,000) | — | — |
| Maturities of available-for-sale securities | 176,000,000 | — | — | — |
| Capital expenditures | (58,800,000) | (72,400,000) | (91,800,000) | (70,600,000) |
| Proceeds from the Department of Defense | 0 | 0 | 20,500,000 | 75,000,000 |
| Increase in equipment under customer usage agreements | (78,200,000) | (57,800,000) | (58,400,000) | (56,600,000) |
| Purchase of equity method investment | — | — | (10,000,000) | — |
| Strategic investments | (35,000,000) | (42,500,000) | — | — |
| Purchase of intellectual property | (15,400,000) | (10,000,000) | 0 | 0 |
| Other activity | — | — | — | 4,500,000 |
| Other activity | (2,900,000) | (2,000,000) | (7,400,000) | — |
| Net cash used in investing activities | (482,700,000) | (781,000,000) | (152,100,000) | (206,300,000) |
| FINANCING ACTIVITIES | ||||
| Proceeds from long-term debt, net of issuance costs | 1,161,000,000 | 0 | 0 | 1,491,200,000 |
| Repayment of long-term debt | (1,197,500,000) | (287,500,000) | (15,000,000) | (1,387,500,000) |
| Proceeds from Senior Notes | — | — | 0 | 0 |
| Repayment of Senior Notes | — | — | 0 | 0 |
| Proceeds from revolving credit line | — | — | — | 0 |
| Repayments under revolving credit line | — | — | 0 | 0 |
| Proceeds from accounts receivable securitization agreement | — | — | 0 | 0 |
| Repayments under accounts receivable securitization agreement | — | 0 | 0 | (248,500,000) |
| Repayment of acquired long-term debt | — | 0 | 0 | (63,700,000) |
| Payments to Noncontrolling Interests | — | — | 0 | 0 |
| Payment of contingent consideration | (1,100,000) | (2,600,000) | (7,600,000) | (12,200,000) |
| Payment of deferred acquisition consideration | 0 | 0 | (800,000) | 0 |
| Repurchases of common stock | (752,900,000) | (835,100,000) | (474,800,000) | (542,100,000) |
| Net proceeds from issuance of common stock under employee stock plans | 38,800,000 | 37,800,000 | 43,000,000 | 33,500,000 |
| Payment of minimum tax withholdings on net share settlements of equity awards | (22,200,000) | (17,400,000) | (24,000,000) | (22,900,000) |
| Payments under finance lease obligations | (3,300,000) | (3,800,000) | (4,000,000) | (3,800,000) |
| Net cash used in financing activities | (777,200,000) | (1,108,600,000) | (483,200,000) | (756,000,000) |
| Effect of exchange rate changes on cash and cash equivalents | 2,100,000 | 8,900,000 | 300,000 | 5,800,000 |
| Net increase (decrease) in cash and cash equivalents | (200,700,000) | (595,500,000) | 416,200,000 | 1,169,200,000 |
| Cash and cash equivalents, beginning of period | 2,160,200,000 | 2,755,700,000 | 2,339,500,000 | 1,170,300,000 |
| Cash and cash equivalents, end of period | 1,959,500,000 | 2,160,200,000 | 2,755,700,000 | 2,339,500,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.